Data on KRAS mutation status and Ang-2 in plasma were available for 156 patients (77 receiving vanucizumab/mFOLFOX-6 and 79 receiving bevacizumab/mFOLFOX-6); 78 (50%) of whom had mutant KRAS tumours (Table 2B). This evidence concerns the gene KRAS and neoplasm.